Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global automated breast ultrasound systems (ABUS) market was valued at USD 1.32 billion in 2024. The market is projected to grow from USD 1.42 billion in 2025 to USD 2.41 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period.
Automated breast ultrasound systems are advanced diagnostic imaging tools designed specifically for breast cancer screening. These systems utilize high-frequency sound waves to automatically generate a series of detailed, three-dimensional (3D) volumetric images of the entire breast, offering a more standardized and operator-independent examination compared to traditional handheld ultrasound. This technology is particularly crucial as a supplemental screening tool for women with dense breast tissue, where mammography has reduced sensitivity. By minimizing operator dependency, ABUS provides consistent and reproducible scans, enhancing diagnostic accuracy.
The market's expansion is primarily fueled by the rising global prevalence of breast cancer and increasing awareness of the limitations of mammography in dense breasts. For instance, approximately 40-50% of women undergoing screening mammography are classified as having dense breasts. Furthermore, technological advancements, such as improved image reconstruction algorithms and integration with artificial intelligence for automated lesion detection, are driving adoption. The competitive landscape is intense, with key players like GE Healthcare, Siemens Healthineers, and Koninklijke Philips N.V. actively launching new systems and securing regulatory clearances to strengthen their market positions, a factor that will continue to stimulate growth.
Rising Global Breast Cancer Incidence
The increasing prevalence of breast cancer worldwide is a primary driver for the automated breast ultrasound systems (ABUS) market. With over 2.3 million new cases diagnosed annually, there is a critical need for effective screening tools, especially for women with dense breast tissue where mammography is less sensitive. This high disease burden creates sustained demand for advanced diagnostic technologies.
Technological Advancements and Procedural Efficiency
Significant technological improvements in ABUS, including enhanced image resolution, 3D volumetric imaging, and integration with artificial intelligence for lesion detection, are propelling market growth. These systems reduce operator dependency and exam time, increasing throughput in busy diagnostic centers and improving standardization of ultrasound screening.
➤ The adoption of adjunct screening guidelines by major radiology societies for women with dense breasts is a pivotal driver, creating a new standard of care and expanding the eligible patient population for ABUS.
Furthermore, growing awareness and advocacy for breast health, coupled with supportive reimbursement policies in several developed countries, are encouraging the adoption of ABUS as a supplemental screening tool, thereby driving market expansion.
MARKET CHALLENGES
High System Cost and Reimbursement Hurdles
The capital investment required for automated breast ultrasound systems is substantial, posing a significant challenge for smaller clinics and facilities in cost-sensitive markets. Additionally, navigating the complex and often inconsistent reimbursement landscape for supplemental screening procedures can deter widespread adoption.
Other Challenges
Operator Training and Workflow Integration
While ABUS reduces operator dependence for image acquisition, it requires trained personnel for system operation and interpretation. Integrating the ABUS workflow, including image review and storage, into existing radiology information systems (RIS) and picture archiving and communication systems (PACS) presents technical and operational hurdles.
Limited Awareness in Emerging Markets
In many developing regions, there is limited awareness among healthcare providers and the public about the benefits of ABUS as an adjunct to mammography. The primary focus often remains on establishing basic mammography services, slowing the penetration of advanced technologies.
Competition from Established and Emerging Modalities
Automated breast ultrasound systems face strong competition from other breast imaging technologies. Digital breast tomosynthesis (DBT), or 3D mammography, is widely adopted and improves cancer detection in dense breasts, directly competing with ABUS. Furthermore, ongoing research into abbreviated breast MRI protocols presents a potential future restraint if they prove to be a more cost-effective supplemental screening option.
Regulatory and Clinical Validation Requirements
Stringent regulatory approvals for medical devices and the need for large-scale, long-term clinical studies to definitively prove the mortality reduction benefit of ABUS screening can slow down market entry and adoption. Demonstrating improved patient outcomes compared to standard care is essential for gaining universal acceptance from the medical community.
Expansion in Emerging Economies
As healthcare infrastructure improves in emerging economies and disposable incomes rise, there is a significant opportunity to introduce ABUS technology. Governments and private healthcare providers in these regions are increasingly investing in advanced diagnostic capabilities to address the growing burden of breast cancer.
Integration of Artificial Intelligence
The integration of AI and deep learning algorithms for automated lesion detection, characterization, and prioritization on ABUS scans represents a major growth opportunity. AI can enhance radiologist efficiency, reduce interpretation time, minimize variability, and potentially improve diagnostic accuracy, making ABUS an even more powerful tool.
Point-of-Care and Mobile Screening Applications
There is growing potential for deploying compact and more portable ABUS units in point-of-care settings, such as primary care clinics, or in mobile screening vans. This can improve access to screening for underserved populations in rural or remote areas, opening up new market segments.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Automated Breast Volume Scanner is emerging as a particularly influential segment due to its advanced capabilities in generating comprehensive 3D volumetric images of the entire breast. This technological superiority allows for more detailed screening and diagnosis, especially in women with dense breast tissue where traditional mammography can be less effective. The demand is being driven by the clinical need for higher diagnostic accuracy and the system's ability to improve workflow efficiency for radiologists by automating the scan acquisition process. |
| By Application |
|
Hospitals represent the cornerstone of the market, acting as the primary adoption center for Automated Breasts Ultrasound Systems. Their leadership is underpinned by high patient volumes, the availability of specialized radiology departments, and the financial capacity to invest in capital-intensive medical imaging technology. Hospitals utilize these systems for both screening asymptomatic women and for diagnostic follow-ups, integrating them into comprehensive breast care programs. The trend towards establishing dedicated breast health centers within large hospital networks further solidifies this segment's dominance. |
| By End User |
|
Radiology Departments are the dominant end users, as they are the clinical units directly responsible for conducting and interpreting breast imaging studies. The adoption of automated systems is heavily influenced by radiologists' preference for technologies that enhance diagnostic confidence, standardize image acquisition to reduce operator dependency, and improve workflow efficiency. These departments value the objective and reproducible datasets produced by automated systems, which are crucial for accurate diagnosis, longitudinal tracking of breast lesions, and facilitating second opinions. |
| By Technology |
|
AI-Integrated Systems are rapidly becoming the most dynamic and forward-looking segment. The integration of artificial intelligence for image analysis and computer-aided detection is a significant technological leap, promising to revolutionize breast ultrasound. These systems offer enhanced capabilities for automated lesion detection, characterization, and risk assessment, which can reduce interpretation time and potentially increase diagnostic accuracy. The growing emphasis on precision medicine and the vast amount of data generated by automated scans create a strong synergy with AI algorithms, positioning this segment for substantial future growth and innovation. |
| By Purchase Model |
|
Subscription/Pay-per-Scan Models are gaining significant traction as a leading procurement strategy, especially among smaller clinics and facilities in cost-sensitive markets. This model lowers the initial capital expenditure barrier, making advanced technology more accessible. It aligns the cost of the system directly with its usage, providing financial flexibility and predictability. Manufacturers are increasingly promoting these models to expand their customer base, as they also facilitate the bundling of ongoing service, software updates, and AI tools, creating a continuous relationship with the healthcare provider beyond the initial sale. |
A concentrated yet dynamic market driven by technological innovation and strategic consolidation
The Automated Breast Ultrasound Systems (ABUS) market is characterized by significant concentration among a few established global players, with the top five companies accounting for a substantial portion of the global revenue share in 2024. These leading corporations, including GE Healthcare, Siemens AG, and Koninklijke Philips NV, leverage their extensive R&D capabilities, broad product portfolios, and strong global distribution networks to maintain dominance. Their market leadership is further reinforced by strategic acquisitions and partnerships aimed at enhancing technological capabilities, such as integrating artificial intelligence for improved lesion detection and workflow efficiency. The competitive intensity is high, with innovation in image quality, patient comfort, and streamlined diagnostic workflows being key differentiators.
Beyond the major players, a number of specialized and emerging companies are carving out significant niches, contributing to market dynamism. Companies such as SuperSonic Imagine, with its proprietary ShearWave Elastography technology, and QView Medical, which focuses on AI-powered CAD software for ABUS, are gaining traction by addressing specific diagnostic challenges. Other notable participants like Canon Medical Systems, Hitachi Ltd., and SonoCine Inc. offer competitive systems, while firms like Metritrack Inc. and Nova Medical Imaging Technology Co. Ltd. cater to particular regional markets or application segments, increasing the competitive pressure.
List of Key Automated Breasts Ultrasound Systems Companies ProfiledMetritrack Inc.
Nova Medical Imaging Technology Co. Ltd.
SonoCine Inc.
SuperSonic Imagine
MedGyn Products, Inc.
Esaote S.p.A.
Fujifilm Holdings Corporation
Samsung Medison
The global market for Automated Breast Ultrasound Systems is on a significant growth trajectory. Valued at a substantial figure in 2024, the market is projected to reach a multi-million dollar valuation by 2032, reflecting a notable Compound Annual Growth Rate (CAGR) over the forecast period. This expansion is primarily driven by the increasing global incidence of breast cancer, positioning ABUS as a critical supplemental screening tool, especially for women with dense breast tissue where mammography alone may be less effective. The demand is further amplified by growing awareness of early cancer detection and technological advancements in imaging.
Other TrendsSegmentation and Application Dynamics
The market is segmented by product type into Automated Breast Ultrasound Systems and Automated Breast Volume Scanners, each capturing a significant share of the global market. In terms of application, hospitals represent the dominant end-user segment due to their high patient volume and need for comprehensive diagnostic capabilities. Ambulatory Surgery Centers are also a key application area, driven by the shift towards outpatient care and cost-effective diagnostic procedures. The "Others" segment includes specialized diagnostic imaging centers.
Intensifying Competition and Regional Market ShiftsThe competitive landscape is characterized by the presence of established global medical technology leaders. The top five players, including Canon Medical Systems, GE Healthcare, Hitachi Ltd., Koninklijke Philips NV, and Siemens AG, collectively held a significant revenue share in 2024. Regionally, the U.S. market is a major contributor, while China's market is projected to experience rapid growth, reaching a multi-million dollar valuation. This indicates a geographical shift with Asia emerging as a high-growth market, influenced by improving healthcare infrastructure and increasing screening programs.
Regional Analysis: Automated Breast Ultrasound Systems MarketEurope
Europe represents a significant and growing market for Automated Breast Ultrasound Systems, characterized by robust public healthcare systems and a strong focus on women's health. The market growth is supported by the implementation of organized breast cancer screening programs in many European countries, which are increasingly recognizing the value of adjunct screening for women with dense breasts. While reimbursement pathways can vary significantly between national health services, there is a clear trend towards acknowledging the clinical utility of ABUS. The presence of stringent CE marking regulations ensures that marketed devices meet high safety and performance standards. Collaborative efforts between academic institutions and industry players foster innovation, particularly in integrating ABUS with other modalities like MRI and developing standardized reporting protocols.
Asia-Pacific
The Asia-Pacific region is experiencing the fastest growth in the ABUS market, driven by improving healthcare infrastructure, rising healthcare expenditure, and growing awareness of breast cancer screening. Countries like Japan, China, and Australia are at the forefront of this expansion. The large and growing patient population, including a significant number of women with dense breast tissue, presents a substantial addressable market. Governments are increasingly investing in national cancer control programs, which is expected to boost the adoption of advanced screening technologies. However, market penetration is uneven, with growth concentrated in urban tertiary care centers, while challenges related to cost sensitivity and the need for specialized training remain in many developing parts of the region.
South America
The South American market for ABUS is in a developing phase, with growth primarily centered in countries with more advanced healthcare systems such as Brazil and Argentina. Market expansion is constrained by economic volatility and limited healthcare budgets, which can restrict investments in high-cost medical imaging equipment. Awareness of dense breast tissue and the need for supplemental screening is gradually increasing among healthcare professionals and the public. The market is largely served by multinational corporations, and adoption is mostly seen in private healthcare settings and major urban hospitals. Regulatory harmonization efforts across the region could potentially streamline market access in the future.
Middle East & Africa
The Middle East & Africa region presents a nascent but promising market for ABUS. Growth is highly concentrated in wealthier Gulf Cooperation Council (GCC) countries, such as the United Arab Emirates and Saudi Arabia, which are investing heavily in modernizing their healthcare infrastructure and promoting advanced medical tourism. In these markets, there is a growing emphasis on women's health initiatives. However, across the broader region, market development is challenged by significant economic disparities, limited healthcare access in rural areas, and a general lack of awareness about supplemental breast screening technologies. The market potential is considerable but will require targeted educational efforts and strategic partnerships to realize.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
極✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
極Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
極Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
高High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems極
Contract research and manufacturing organizations
Investors, consultants, and policy makers極
-> Global automated breast ultrasound systems market was valued at USD 1.32 billion in 2024 and is expected to reach USD 2.41 billion by 2032.
-> Key players include GE Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Canon Medical Systems, and Hitachi Ltd.極, among others.
-> The market is projected to exhibit a compound annual growth rate (CAGR) of 7.8% during the forecast period.
-> Asia-Pacific is the fastest-growing region, while North America remains a dominant market.
-> Key growth drivers include rising global prevalence of breast cancer, increasing awareness of limitations of mammography in dense breasts, and technological advancements in imaging and AI integration.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates